CJ Bioscience
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
CJ Bioscience studies the trillions of microbes living in the human gut, collectively called the microbiome, and uses that research to develop new medicines, genomic analysis tools, and consumer gut-health services.
Its customers include hospitals and medical institutions that use its GUT INSIDE diagnostic service, researchers who use its EzBioCloud microbial genomics platform, and general consumers who use its SMILE GUT gut-health app. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company is actively shifting its business mix away from a pure drug-development model toward a broader portfolio that combines clinical-stage drug candidates with revenue-generating health and wellness services.
Summary is AI-generated and may contain errors · figures from DART filings
The filing notes that the company plans to link its health and wellness services with wellness-related businesses within its broader corporate group, though no specific group entity is named.
CJ Bioscience in five facts
What does CJ Bioscience do?
CJ Bioscience studies the trillions of microbes living in the human gut, collectively called the microbiome, and uses that research to develop new medicines, genomic analysis tools, and consumer gut-health services.
Where is CJ Bioscience listed and in which sector?
CJ Bioscience (Korean name: CJ 바이오사이언스) trades under KRX code 311690 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is CJ Bioscience?
Its market capitalisation was US$37.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were CJ Bioscience's latest annual revenue and operating profit?
For fiscal year 2025, CJ Bioscience reported revenue of US$2.8M, an operating loss of US$18.7M and a net loss of US$18.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 6.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.